




- (51) International Patent Classification:
G01N 33/543 (2006.01) *G01N 33/53* (2006.01)
- (21) International Application Number:
PCT/US2016/042331
- (22) International Filing Date:
14 July 2016 (14.07.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/192,481 14 July 2015 (14.07.2015) US
- (71) Applicant: UNIVERSITY OF IOWA RESEARCH
FOUNDATION [US/US]; 112 N. Capitol Street, 6
Gilmore Hall, Iowa City, Iowa 52242-5500 (US).

- (72) Inventors; and
(71) Applicants : WIEMER, David, F. [US/US]; 112 N. Capitol Street, 6 Gilmore Hall, Iowa City, Iowa 52242-5500 (US). BARNEY, Rocky, J. [US/US]; 112 N. Capitol Street, 6 Gilmore Hall, Iowa City, Iowa 52242-5500 (US). WIEMER, Andrew [US/US]; 69 North Eagleville Road, Storrs, Connecticut 06269-3092 (US).
- (74) Agents: HARRIS, Robert, J. et al.; Viksnins Harris & Padys PLLP, 7851 Metro Parkway, Suite 325, Bloomington, Minnesota 55425 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: FLUORESCENT PRODRUGS

Figure 1



(57) **Abstract:** The invention provides a drug conjugate comprising: 1) a therapeutic agent that comprises a phosphate, phosphonate, carboxy, or phosphoramidate group, and 2) a fluorescent group linked to the phosphate, phosphonate, carboxy, or phosphoramidate group to form the corresponding ester and salts thereof. The conjugates are useful for therapy and as probes. The invention also provides therapeutic methods for treating diseases with conjugates of the invention as well as methods for determining optimal dosages of a conjugate or a therapeutic agent for a given patient using a conjugate of the invention



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

FLUORESCENT PRODRUGS

Related Application

This application claims priority to U.S. Provisional Patent Application No.

5 62/192,481 filed July 14, 2015, the entirety of which is incorporated herein by reference.

Background of the Invention

A variety of drugs and other biologically interesting molecules contain phosphate or phosphonate substructures (Westheimer, F.H., *Science*, **1987**, 235, 4793, 1173-1178).

However, the negative charge of such compounds at physiological pH frequently acts as a
10 barrier to rapid cellular entry (Kornberg, R.D., et al., *Proceedings of the National Academy of Sciences of the United States of America*, **1972**, 69, 6, 1508-1513). As such, development of cell-cleavable protecting groups that increase in vivo absorption is of great interest with several phosphonate “prodrugs” recently achieving clinical status (Wiemer, A.J. and D.F. Wiemer, *Top Curr Chem*, **2015**, 360, 115-60). While cell-cleavable phosphoester (Lee, W.A.
15 and J.C. Martin, *Antiviral Research*, **2006**, 71, 254-259) and phosphoamidate (Pertusati, F., et al., *Antivir Chem Chemother*, **2012**, 22, 5, 181-203) protecting groups effectively increase cellular uptake, it remains challenging to use these compounds to assess biological mechanisms in real-time because concentrations of compounds in live cells cannot be readily assessed.

20 (E)-4-Hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) is an intermediate of isoprenoid metabolism found in bacteria and other microorganisms (Wiemer, A.J., C.-H.C. Hsiao, and D.F. Wiemer, *Current Topics in Medicinal Chemistry*, **2010**, 10, 18, 1858-1871). HMBPP synthesis is required for bacteria growth (Gerdes, S.Y., et al., *J Bacteriol*, **2003**, 185, 19, 5673-84) and it also functions as a potent pathogen-associated molecular pattern (PAMP)
25 that stimulates an immune response from human gamma delta T cells (Morita, C.T., et al., *Immunological Reviews*, **2007**, 215, 59-76). However, the mechanisms of HMBPP immunostimulation are currently a topic of intense debate (Karunakaran, M.M. and T. Herrmann, *Frontiers in Immunology*, **2014**, 5; and Harly, C., C.-M. Peigné, and E. Scotet, *Frontiers in Immunology*, **2014**, 5). Therefore, development of HMBPP analogs which can
30 contribute to understanding its immunostimulatory mechanism are desired (Wiemer, D.F. and A.J. Wiemer, *Biochem Pharmacol*, **2014**, 89, 3, 301-12).

Currently there is a need for agents that are useful for treating or preventing diseases (e.g. cancer) and for cancer immunotherapy agents. There is also a need for detectable probes that can be used to study the pharmacology of diseases and therapeutic agents.

Summary of the Invention

5 Enzymatically-cleavable protecting groups are often required for efficient cellular delivery of drugs or chemical probes that contain carboxylates, phosphonates, and phosphates. Although several protecting groups have achieved clinical success, it remains difficult in live cells to use prodrugs to clarify biological mechanisms in space and time with precise clarity. The invention provides a protecting strategy that uses fluorescent ester
10 derivatives (e.g. 7-methoxycoumarin-3-carboxylic acid (MOCCA or CCOM) ester derivatives) as carboxylate, phosphonate, and phosphate protecting groups. The fluorescent protecting groups deliver the resulting conjugates intracellularly, with high efficiency and low toxicity. The free fluorescent protecting group, but not the corresponding esters, typically exhibit strong pH sensitivity, allowing for no-wash kinetic analysis of is biological
15 deprotection by conventional fluorescence plate readers. Modified phosphoantigens have been found to display similar biological activity to pivaloyloxymethyl (POM)-modified phosphoantigens and reveal that phosphoantigen esters are internalized into cells within hours of administration. The conjugates of the invention include fluorescent protecting groups that are both functional drug delivery tools and useful biological probes for monitoring the
20 exquisite rates of cellular uptake of the conjugates.

 Accordingly the invention provides a conjugate comprising: 1) a therapeutic agent that comprises a phosphate, phosphonate, carboxy, or phosphoramidate group, and 2) a fluorescent group linked to the phosphate, phosphonate, carboxy, or phosphoramidate group to form the corresponding ester, or a salt thereof.

25 The invention also provides a pharmaceutical composition comprising a conjugate of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

 The invention also provides a conjugate of the invention, or a pharmaceutically acceptable salt thereof, for use in medical therapy.

30 The invention also provides a conjugate of the invention, or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of cancer.

The invention also provides the use of a conjugate of the invention, or a pharmaceutically acceptable salt thereof, to prepare a medicament for treating cancer in an animal (e.g. a mammal such as a human).

5 The invention also provides synthetic processes and intermediates disclosed herein that are useful for preparing a conjugate of the invention.

The invention also provides a conjugate of the invention (e.g. a conjugate comprising a therapeutic agent that has anti-infective activity or immune modulating activity), or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of infections and/or immune disorders.

10 The invention also provides the use of a conjugate of the invention (e.g. a conjugate comprising a therapeutic agent that has anti-infective activity or immune nodulating activity), or a pharmaceutically acceptable salt thereof, to prepare a medicament for treating infections and/or immune disorders in an animal (e.g. a mammal such as a human).

15 Phosphoantigen-sensitive V γ 9V δ 2 T cells are important responders to infections and malignancy. However, the mechanisms by which phosphoantigens stimulate V γ 9V δ 2 T cells are unclear. Phosphoantigen prodrugs were prepared and used to demonstrate that intracellular delivery of phosphoantigens is required for their activity. The pivaloyloxymethyl prodrug provides stronger stimulation of V γ 9V δ 2 T cells from human peripheral blood and greater ability to induce lysis of Daudi lymphoma cells relative to the previously most potent
20 compound, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP). Using molecular approaches, nuclear magnetic resonance (NMR) spectroscopy and isothermal titration calorimetry (ITC) a high binding affinity between phosphoantigens and the intracellular region of butyrophilin 3A1 (BTN3A1) has been shown, localized to the PRY/SPRY (B30.2) domain but also affecting the membrane proximal region. Collectively, these findings not
25 only promote a novel compound/approach for cancer immunotherapy, but also unravel fundamental aspects of the molecular mechanisms of V γ 9V δ 2 T cell activation by phosphoantigens.

Brief Description of the Figures

Figure 1. A) Expected cellular metabolism of MOCCA-Me-C-HMBP. B) Expected
30 cellular metabolism of MOCCA-POM-C-HMBP.

Figure 2. MOCCA-Me-C-HMBP is a potent gamma delta T cell agonist. A) PBMCs

were stimulated with MOCCA-Me-C-HMBP and phenotyping was performed to quantify the percentages of cells expressing both the gamma delta TCR and the pan T cell marker CD3. HMBPP was used as a positive control. MOCCA-Me-C-HMBP and POM-Me-C-HMBP were evaluated at a concentration (1 μ M) previously shown to be maximal for POM-Me-C-HMBP. Data is representative from 3 independent experiments. B) Quantification of gamma delta T cell proliferation in response to MOCCA-Me-C-HMBP and POM-Me-C-HMBP, n=3. C) Dose response curves for MOCCA-Me-C-HMBP versus Me-C-HMBP.

Figure 3. MOCCA prodrugs effectively sensitize K562 cells to T cell mediated lysis.

Figure 4. pH and protein dependent changes in MOCCA fluorescence.

Figure 5. MOCCA prodrugs are esterase cleavable. Kinetics of stability in A) PBS or B) 50% human plasma in PBS. C) Rate of decay fits a second order kinetics. D) Thin layer chromatography of MOCCA-Me-C-HMBP. The compound was exposed to 50% human plasma for the indicated times and resolved by TLC. Metabolism was assessed by disappearance of the compound and appearance of the MOCCA metabolite.

Figure 6. MOCCA prodrugs rapidly enter cells.

Figure 7. The MOCCA protecting group exhibits little cellular toxicity. Effects of MOCCA prodrugs versus POM analogs on cell proliferation in which measurable IC₅₀ values were obtained. Indicated cell lines were treated for 72 hours with the compounds at shown concentrations and evaluated by QB assay. Statistical significance was evaluated using a paired t-test at 100 μ M concentrations.

Detailed Description

It will be appreciated by those skilled in the art that conjugates having a chiral center may exist in and be isolated in optically active and racemic forms. Some conjugates may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a conjugate of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase).

The term "amino acid," comprises the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g. phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, α -methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine). The term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g. acetyl or benzyloxycarbonyl), as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a (C₁-C₆)alkyl, phenyl or benzyl ester or amide; or as an α -methylbenzyl amide). Other suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, T.W. Greene, *Protecting Groups In Organic Synthesis*; Wiley: New York, 1981, and references cited therein). An amino acid can be linked to the remainder of a compound of formula I through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.

The conjugates of the invention comprise a therapeutic agent that is linked to a fluorescent group through a linkage that is readily degradable once the compound is within the cell. As used herein, "linked" includes a direct covalent bond as well as covalent attachment through a linking group. Suitable linking groups include a (C₁-C₆) alkylene (e.g. methylene), an acyloxy ester of a phosphonic or carboxylic acid ester, or a phosphoramidate derivative of a phosphonic acid where either the amide or the ester (or both) include a fluorescent moiety, attached by a variable linker. Suitable fluorescent groups including fluorescein, coumarin, FITC, and CFSE, and derivatives thereof.

The term "therapeutic agent" includes compounds that have a therapeutic or biological effect on an animal (e.g. a mammal). In one embodiment, the therapeutic agent excludes nucleic acids (e.g. DNA and RNA). In one embodiment, the therapeutic agent excludes proteins (e.g. proteins having five or more amino acids in sequence). In one embodiment, the therapeutic agent excludes nucleic acids (e.g. DNA and RNA) and proteins (e.g. proteins having five or more amino acids in sequence). In one embodiment the therapeutic agent is a small organic molecule (e.g. a small molecule having a molecular weight of less than about 800 u). In one embodiment the therapeutic agent is a small organic

molecule having a molecular weight of less than about 600 u. In one embodiment the therapeutic agent is a small organic molecule having a molecular weight of less than about 500 u. In one embodiment the therapeutic agent is a small organic molecule having a molecular weight of at least about 200 u and less than about 800 u. In one embodiment the therapeutic agent is a small organic molecule having a molecular weight of at least about 200 u and less than about 600 u. In one embodiment the therapeutic agent is a small molecule that has anti-cancer (e.g. anti-leukemia) properties. In one embodiment the therapeutic agent is a small molecule that has anti-infective properties. In one embodiment the therapeutic agent is a small molecule that has immune-modulating properties.

In one embodiment the invention provides a method comprising: obtaining a biological sample from a mammal comprising one or more cells; contacting a conjugate of the invention with the biological sample under conditions whereby the conjugate enters the cells; and measuring the conjugate's fluorescent intensity within the cells or the decrease in fluorescence intensity outside the cells. In one embodiment, such a method can be used to determine an appropriate dose of the conjugate or the therapeutic agent comprised therein to administer to the mammal. For example, in order to determine the appropriate dosage of a therapeutic agent that has anti-leukemia properties the invention provides a method comprising obtaining white cells from a mammal by drawing blood from the mammal, contacting the white cells with a conjugate of the invention that comprises a therapeutic agent having anti-leukemia properties to establish the rate/amount of uptake, and using the rate or uptake to design a specific dosage (e.g. of the conjugate or of the therapeutic agent) for that mammal.

When a bond in a conjugate formula herein is drawn in a non-stereochemical manner (e.g. flat), the atom to which the bond is attached includes all stereochemical possibilities.


When a bond in a conjugate formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge), it is to be understood that the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted unless otherwise noted. In one embodiment, the conjugate may be at least 51% the absolute stereoisomer depicted. In another embodiment, the conjugate may be at least 60% the absolute stereoisomer depicted. In another embodiment, the conjugate may be at least 80% the absolute stereoisomer depicted. In another embodiment, the conjugate may be at least

90% the absolute stereoisomer depicted. In another embodiment, the conjugate may be at least 95 the absolute stereoisomer depicted. In another embodiment, the conjugate may be at least 99% the absolute stereoisomer depicted.

A prodrug is a compound that can be converted under physiological conditions to a therapeutic or otherwise biologically active agent. The term "prodrug moiety" includes cleavable groups that can be appended to a therapeutic agent to form a prodrug. For example, the term prodrug moiety includes groups that form cleavable esters, cleavable anhydrides, and cleavable amides, such as amino acid residues and polypeptide chains of two or more (e.g., two, three or four) amino acid residues that can be linked to a therapeutic agent to form a prodrug.

Phosphonate and phosphate prodrug moieties are known to include acyloxy esters and phenyl (or substituted phenyl) phosphoramidates (Wiemer, A.J. and D.F. Wiemer, *Top Curr Chem*, 2015, 360, 115-60). In one embodiment, the term prodrug moiety is a "cell cleavable group," which can be cleaved under physiological conditions inside a cell to provide a therapeutic agent, for example the pivaloyloxymethyl ester POM group. For additional examples of prodrug derivatives, see a) *Design of Prodrugs*, edited by H. Bundgaard, (Elsevier, 1985) and *Methods in Enzymology*, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) *A Textbook of Drug Design and Development*, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs," by H. Bundgaard p. 113-191 (1991); c) H. Bundgaard, *Advanced Drug Delivery Reviews*, 8:1-38 (1992); d) H. Bundgaard, et al., *Journal of Pharmaceutical Sciences*, 77:285 (1988); and e) N. Kakeya, et al., *Chem. Pharm. Bull.*, 32:692 (1984).

Processes and synthetic intermediates that are useful for preparing conjugates of the invention are provided as further embodiments of the invention and are illustrated by the Schemes and Examples herein. In preparing conjugates of the invention, protection of certain functional groups may be beneficial. The desirability of such protection will vary depending on the nature of the functionality and the conditions of the preparation methods. For example, when preparing a conjugate comprising a therapeutic agent of formula:



wherein R¹ is H, it may be beneficial to prepare a corresponding protected compound wherein R¹ is a protecting group or prodrug moiety. Compounds comprising one or more

protecting groups are useful as synthetic intermediates for preparing other conjugates of the invention. Compounds comprising one or more protecting groups may also possess useful biological activities. Accordingly, in one embodiment the invention provides compounds and conjugates that comprise one or more protecting groups. Suitable protecting groups, as well
5 as suitable conditions for their incorporation and removal are known, see T. W. Greene, *et al.* Greene's Protective Groups in Organic Synthesis. New York: Wiley Interscience, 2006.

In cases where a conjugate is sufficiently basic or acidic, a salt of a conjugate can be useful as an intermediate for isolating or purifying another conjugate. Additionally, administration of a conjugate as a pharmaceutically acceptable acid or base salt may be
10 appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α -ketoglutarate, and α -glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic conjugate such as an amine with
15 a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

The conjugates can be formulated as pharmaceutical compositions and administered
20 to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.

Thus, the conjugates may be systemically administered, e.g., orally, in combination
25 with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the conjugate may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions,
30 syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active conjugate. The percentage of the compositions and preparations may, of

course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of conjugate in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the following:

5 binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition
10 to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the conjugate, sucrose or fructose as a sweetening agent, methyl and propylparabens as
15 preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the conjugate may be incorporated into sustained-release preparations and devices.

The conjugate may also be administered intravenously or intraperitoneally by infusion
20 or injection. Solutions of the active conjugate can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion can include sterile
25 aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for
30 example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable

mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the conjugate in the required amount in the appropriate solvent with various types of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

For topical administration, the conjugates may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.

Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present conjugates can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.

Examples of useful dermatological compositions which can be used to deliver the conjugates to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).

5 Useful dosages of the conjugates can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

10 The amount of the conjugate, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.



15 The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

 The invention will now be illustrated by the following non-limiting Examples.

EXAMPLES


Example 1. Synthesis of a Representative Conjugate of the Invention (Mono MOCCA mono methyl phosphonate)

A representative conjugate of the invention was prepared as illustrated and described below.


**a. Preparation of 7-Methoxy-2-oxo-2H-chromene-3-carboxylic acid**

2-Hydroxy-4-methoxybenzaldehyde (2.99 g, 19.7 mmol), Meldrum's acid (2.88 g, 19.8 mmol), and piperdinium acetate (64 mg, 0.44 mmol) were dissolved in ethanol, the solution was heated at reflux for 3 hours, and then it was cooled to 0 °C in an ice bath resulting in a precipitate. The precipitate was isolated by filtration and recrystallized from hot ethanol. The product was isolated by filtration to give a slightly yellow solid in 96% yield (4.17 g), with 1H NMR data consistent with literature data (Caron, K., et al., *Org. Biomol. Chem.* **2011**, 9, 185-197).


b. Preparation of 7-Methoxy-2-oxo-2H-chromene-3-carboxylic acid chloromethyl ester 2.



5 The carboxylic acid **1** (1.10 g, 5.02 mmol) and KOH (0.28 g, 5.02 mmol) were dissolved in ethanol and the solution was heated at reflux for 4 hours.² After the solution was concentrated *in vacuo*, the resulting solid was dissolved in water (20 mL) and dichloromethane (20 mL) and the solution was cooled to 0 °C. Potassium carbonate (6.93 g, 50.0 mmol), tetrabutylammonium hydrogen sulfate (0.41 g, 1.21 mmol), and chloromethyl chlorosulfate (1.52 mL, 15.1 mmol) were added. The solution was stirred vigorously for 10 mins and then allowed to stir for 48 hr. The organic portion was separated and the aqueous layer was extracted with dichloromethane. The organic portions were combined and washed with brine, dried (NaSO₄), and filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (8% EtOH in dichloromethane) to give the desired product **2** (1.1 g, 80%): ¹H NMR (400 MHz, CDCl₃) δ 8.62 (s, 1H), 7.55 (d, *J* = 8.8 Hz, 1H), 6.93 (dd, *J* = 8.8, 2.4 Hz, 1H), 6.83 (d, *J* = 2.4 Hz, 1H), 5.95 (s, 2H), 3.93 (s, 3H); ¹³C NMR (75 MHz, DMSO) δ 165.4, 160.6, 157.3, 155.7, 151.0, 132.0, 113.4, 111.2, 111.0, 100.2, 69.8, 56.2; HRMS (ES⁺) calcd for C₁₂H₉O₅ClNa [M⁺ + Na] 291.0036; found: 291.0038. See Ingram, A. M., et al., *Org. Biomol. Chem* **2006**, 4, 2869-2873 for related synthetic processes.




c. Preparation of Ammonium salt 4

**4**

(5-Hydroxy-4-methyl-pent-3-enyl)-phosphonic acid dimethyl ester (Hsiao, C.-H., et al., *Chem. Biol. (Oxford, U. K.)* **2014**, 21, 945-954; 0.18 g, 0.87 mmol) and 1,4-diazabicyclo[2.2.2] octane (0.09 g, 0.87 mmol) were dissolved in acetonitrile and the reaction mixture was heated at reflux overnight. The solution was concentrated in vacuo and used without further purification, giving the desired product **4** as a brown residue in 61% yield (0.17 g): ^1H NMR (400 MHz, D_2O) δ 5.38–5.44 (m, 1H), 3.89 (s, 2H), 3.46 (d, $J_{\text{PH}} = 10.5$ Hz, 3H), 3.30–3.33 (m, 6H), 3.10–3.15 (m, 6H), 2.15–2.19 (m, 2H), 1.53–1.61 (m, 5H); ^{13}C NMR (125 MHz, D_2O) δ 135.3, 127.1 (d, $J_{\text{PC}} = 16.6$ Hz), 68.1, 54.6, 54.6, 54.6, 52.2, 52.2, 52.1, 51.6 (d, $J_{\text{PC}} = 5.4$ Hz), 25.8 (d, $J_{\text{PC}} = 134.0$ Hz), 21.8 (d, $J_{\text{PC}} = 4.8$ Hz), 12.9; ^{31}P NMR (161 MHz, CDCl_3) + 29.3; HRMS(ES $^-$) calcd for $\text{C}_7\text{H}_{14}\text{O}_4\text{P}$ [M^- - DABCO] 193.0641; found: 193.0630.

15 d. Preparation of Phosphonate 5.


**5**

The phosphonate salt **4** (170 mg, 0.53 mmol), sodium iodide (0.12 g, 0.80 mmol), and chloromethyl ester **2** (0.21 g, 0.80 mmol) were dissolved in acetonitrile (5 mL) and the resulting solution was heated at reflux overnight. The reaction was then quenched by addition of brine and extracted with dichloromethane. The combined organic portions were washed with saturated $\text{Na}_2\text{S}_2\text{O}_3$, dried (NaSO_4), and filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (5% EtOH in dichloromethane) to give the product **5** as a white solid (142 mg, 63%): ^1H NMR (500 MHz,


CDCl₃) δ 8.59 (s, 1H), 7.51 (d, J = 8.6 Hz, 1H), 6.88 (dd, J = 8.6 Hz, 2.2 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H), 5.84 (d, J_{PH} = 13.1 Hz, 2H), 5.37–5.39 (m, 1H), 3.93 (s, 2H), 3.89 (s, 3H), 3.74 (d, J_{PH} = 10.9 Hz, 3H), 2.41 (br s, 1H), 2.28–2.35 (m, 2H), 1.86–1.93 (m, 2H), 1.60 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.8, 161.7, 157.8, 156.5, 150.4, 136.4 (d, J_{PC} = 1.5 Hz), 131.1 (d, J_{PC} = 15.9 Hz), 113.9, 112.0, 111.4, 100.3, 82.2 (d, J_{PC} = 6.0 Hz) 67.9, 56.0, 52.0 (d, J_{PC} = 7.1 Hz), 25.5 (d, J_{PC} = 139.4 Hz), 20.3 (d, J_{PC} = 4.9 Hz), 13.5; ³¹P NMR (202 MHz, CDCl₃) + 33.8; HRMS (ES⁺) calcd for C₁₉H₂₄O₉P [(M + H)⁺] 427.1158; found 427.1164.

Example 2. Synthesis of a Representative Conjugate of the Invention (Mono MOCCA mono POM phosphonate)

A representative conjugate of the invention was prepared as illustrated and described below.




a. Preparation of Phosphonate ester 6




5 (4-Methyl-pent-3-enyl)-phosphonic acid dimethyl ester (**3**, 1.02 g, 5.29 mmol), sodium iodide (1.63 g, 10.9 mmol), and chloromethyl pivalate (2.43 mL, 16.7 mmol) were dissolved in acetonitrile (5 mL) and the solution was heated at reflux overnight. The reaction was quenched by addition of water and extracted with diethyl ether. The combined organic portions were washed with Na₂S₂O₃, dried (NaSO₄), and filtered, and the filtrate was
 10 concentrated *in vacuo*. The residue was purified by column chromatography (1:1 Et₂O/hexanes) to afford the product **6** as a clear oil (1.17 g, 57%). Both the ¹H and ³¹P NMR data were consistent with literature data (Hsiao, C.-H., et al., *Chem. Biol. (Oxford, U. K.)* **2014**, *21*, 945-954).

15 b. Preparation of Phosphonate ester 7




The phosphonate ester **6** (0.60 g, 1.52 mmol), selenium dioxide (0.08 g, 0.76 mmol), *p*-hydroxybenzoic acid (0.10 g, 0.76 mmol), and *tert*-butylhydroperoxide (0.74 mL, 4.56
 20 mmol) were added to dichloromethane (10 mL). After the reaction mixture was cooled to 0 °C and allowed to stir overnight, it was quenched by addition of brine and extracted with dichloromethane. The combined organic portions were washed with saturated Na₂S₂O₃, dried (Na₂SO₄), and filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (ether) and the product **7** was isolated as a yellow oil (270 mg,
 25 44%). Both the ¹H and ³¹P NMR data were consistent with literature data (Hsiao, C.-H., et al., *Chem. Biol. (Oxford, U. K.)* **2014**, *21*, 945-954).

c. Preparation of Phosphonate salt **8**



Ester **7** (0.47 g, 1.15 mmol) and 1,4-diazabicyclo[2.2.2]octane (0.13 g, 1.15 mmol) were dissolved in acetonitrile and the reaction mixture was heated at reflux overnight. The reaction was quenched by addition of ether and extracted with water. The aqueous portions were combined and concentrated *in vacuo*, giving the desired product **8** as a brown residue (390 mg, 68%) that was used in the following reaction without further purification.

d. Preparation of Mixed ester **9**



The salt **8** (0.20 g, 0.39 mmol), sodium iodide (0.09 g, 0.59 mmol), and 7-methoxy-2-oxo-2H-chromene-3-carboxychloromethyl ester (**2**, 0.16 g, 0.59 mmol) were dissolved in acetonitrile (5 mL). The resulting solution was heated at reflux overnight, and then quenched by addition of brine and extracted with dichloromethane. The organic portions were washed with saturated Na₂S₂O₃, dried (NaSO₄), and filtered, and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (5% EtOH in dichloromethane) to afford the desired product **9** as a white solid (9 mg, 6%): ¹H NMR (400 MHz, CDCl₃) δ 8.64 (s, 1H), 7.56 (d, *J* = 8.9 Hz, 1H), 6.92 (dd, *J* = 8.9 Hz, 2.4 Hz, 1H), 6.83 (d, *J* = 2.4 Hz, 1H), 5.87–5.90 (m, 2H), 5.66–5.76 (m, 2H), 5.39–5.44 (m, 1H), 4.43 (s, 2H), 3.93 (s, 3H), 2.31–2.41 (m, 2H), 1.91–2.01 (m, 2H), 1.65 (s, 3H), 1.58 (br s, 1H), 1.25 (s, 9H); ³¹P NMR (161 MHz, CDCl₃) δ 32.4.

Example 3. Conjugate Evaluation

Reagents and supplies

PE-conjugated anti-human CD3 was obtained from eBioscience (San Diego, CA).
5 Human interleukin 2 was obtained from Miltenyi (San Diego, CA). Annexin-V FITC was obtained from BD Biosciences (San Jose, CA). HMBPP was obtained from Echelon Biosciences (Salt Lake City, UT). CellQuantiBlue was obtained from BioAssay Systems (Hayward, CA). FITC-anti-human gamma delta TCR antibody (5A6.E91) and DiD cell stain was purchased from Thermo Fisher Scientific (Rockford, IL). Fetal bovine serum and all
10 other tissue culture supplies also were obtained from Thermo Fisher. Polyester backed silica G plates, with UV 256 were obtained from Sorbtech technologies (Norcross, GA). Human PMBCs were isolated from blood from Research Blood Components (Brighton, MA). K562 cells were obtained from ATCC (Manassas, VA).

15 *Cell culture*

K562 cells were cultured in fresh K562 media (RPMI-1640, 10% heat-inactivated Fetalclone III, 1x penicillin/streptomycin). Daudi and RPMI-8226 cells were cultured in fresh Daudi/RPMI media (RPMI-1640, 10% heat-inactivated FBS, 1x penicillin/streptomycin). Gamma delta T cells were cultured as described previously [12]. Briefly, cells were expanded
20 from peripheral blood mononuclear cells in fresh T cell media (RPMI-1640, 10% heat-inactivated FBS, 1x HEPES, pyruvate, non-essential amino acids, penicillin/streptomycin, beta-mercaptoethanol) and added to 6-well plates. Cells were stimulated with test compounds for three days at concentrations indicated in the text. Cells were washed twice then cultured for another eleven days after compound removal. Human interleukin 2 (5 ng/mL) was
25 supplemented every three days. Experiments were performed at least three times independently using at least two different blood donors.

Thin layer chromatography

Compounds were exposed to cells, plasma, media, or PBS as indicated in the text in
30 100 μ L volumes. Compounds were extracted from all biological mixtures using 200 μ L of organic solvent containing 95% dichloromethane, 5% ethanol, and 0.25% glacial acetic acid.

Extracts were separated by normal phase flash chromatography using 95% dichloromethane, 5% ethanol, and 0.25% glacial acetic acid as the mobile phase. Compounds were visualized under UV light.

5 *Flow cytometry*

Total gamma delta TCR was labeled using FITC-anti-human Pan gamma delta TCR antibody and CD3 was labeled using PE-conjugated anti-human CD3 as described [12].

Killing assay

10 The killing assay was performed as described with slight modification [12, 13]. T cells were expanded from PMBCs by stimulation with 0.01 μ M HMBPP. Cells were purified by negative selection using a kit (Miltenyi). K562 cells were stained with DiD (2 minutes in 4 μ M DiD in BSA/PBS), quenched by addition of an equal volume of FBS, and washed twice in T cell media. 6×10^3 K562 cells were mixed with 3×10^4 T cells and test compounds to
15 final volume of 100 μ L. Mixtures were incubated for 4 hours at 37 degrees then placed on ice for 5 minutes. Annexin V FITC (3 μ L) was added for 15 minutes on ice, then cells were diluted by addition of 200 μ L binding buffer (BD) and immediately analyzed by flow cytometry.

20 *Proliferation assay*

To assess K562 proliferation, 10000 cells/well were added to 96-well plates in 100 μ L K562 media in the presence of test compounds. Similarly, experiments with Daudi cells were initiated at 5000 cells/well and RPMI8226 cells initiated at 6000 cells/well. The cell concentrations were determined by prior dose response experiments to maximize
25 proliferation rates. Cells were allowed to proliferate for 72 hours. During the last 2 hours, cells were labeled with 10 μ L of CellQuantBlue reagent and scanned with a Victor plate reader.

Quantification of cellular uptake

30 Compounds were exposed to PBS, K562 cells in PBS, or 50% pooled human plasma in PBS. K562 cells were used at a concentration of 1 million per mL. The fluorescence was

detected using a Victor X5 plate reader with excitation at 355 nm and emissions at 405. Compounds were mixed with each biological matrix to a final concentration of 10 μ M on ice. A baseline reading was measured. Compounds were incubated for one hour at 37 °C and subsequent readings were taken every 15 minutes.

5

Statistics

One-way ANOVA was used to calculate statistical significance. Comparisons were done relative to the control. Columns in bar graphs represent the mean +/- standard deviation. An α level of 0.05 was used.

10

Results

MOCCA compounds have low cytotoxicity

The ideal prodrug protecting group would exhibit low cellular toxicity. To establish the effects of the novel MOCCA protecting group on cell viability, the MOCCA compounds were evaluated for their ability to inhibit proliferation of several established cell lines. Notably, the MOCCA compound alone (**1**) exhibited no cellular toxicity in K562, Daudi, RPMI-8226, or Jurkat cells when they were exposed for 72 hours at concentrations up to 100 μ M (Table 1). Additionally, treatment of K562 cells with either of the two MOCCA prodrugs also displayed no cellular toxicity when they were exposed for 72 hours at concentrations up to 100 μ M. In RPMI-8226 and Daudi cells, weak but measurable IC₅₀ values were observed for both the POM and MOCCA versions of C-HMBP that did not differ significantly between cell lines (Table 1, Figure 7). However, differences were observed between the POM and MOCCA versions of C-HMBP in Jurkat cells and the POM and MOCCA versions of Me-C-HMBP in RPMI-8226 cells at concentrations of 100 μ M. In all cases, the toxicity was generally weak and toxic concentrations were much higher than the EC₅₀ values for stimulation of V γ 9V δ 2 T cells.

Table 1. 72 hour IC₅₀ values in selected cell lines.

Compound	K562	RPMI-8226	Daudi	Jurkat
MOCCA (1)	>100 μ M	>100 μ M	>100 μ M	>100 μ M
C-HMBP	>100 μ M	>100 μ M	>100 μ M	>100 μ M
POM ₂ -C-HMBP (7)	>100 μ M	44 μ M	58 μ M	>100 μ M
MOCCA-POM (9)	>100 μ M	43 μ M	56 μ M	53 μ M
Me-C-HMBP (4)	>100 μ M	>100 μ M	>100 μ M	>100 μ M
POM-Me-C-HMBP	>100 μ M	>100 μ M	>100 μ M	>100 μ M
MOCCA-Me-C-HMBP (5)	>100 μ M	64 μ M	>100 μ M	>100 μ M

MOCCA compounds have potent cell activity

The MOCCA prodrugs were also evaluated in a functional assay of their ability to stimulate proliferation of primary human gamma delta T cells. Dose response experiments were performed with the experimental compounds- MOCCA-Me-C-HMBP and MOCCA-POM-C-HMBP. POM-Me-C-HMBP, POM₂-C-HMBP, Me-C-HMBP, C-HMBP or HMBPP were used as positive controls. Unstimulated cells were used as a negative control. Cells were treated for 72 hours with test compounds, washed, then expanded for 11 additional days prior to quantification to assess proliferation. Both MOCCA-Me-C-HMBP and MOCCA-POM-C-HMBP functioned as a gamma delta T cell agonist, causing a large expansion of the population of cells that express both CD3 and the V γ 9V δ 2 T cell receptor as assessed by surface staining (Fig 2A). This finding demonstrates that the MOCCA protecting group can effectively deliver a phosphonate payload, resulting in biological activity.

The agonist activity of POM-Me-C-HMBP was not statistically different from that of POM-Me-C-HMBP (Fig 3B). Dose response curves (Fig 3C) allowed us to determine that the MOCCA-Me-C-HMBP had an EC₅₀ of 0.018 μ M while its analog Me-C-HMBP displays an EC₅₀ of 23 μ M. Therefore the MOCCA protecting strategy offered a 1300 fold increase in activity in this assay. The activity MOCCA-Me-C-HMBP was also slightly lower than the published EC₅₀ value of 0.50 μ M that we obtained for POM-Me-C-HMBP (Hsiao, C.H., et al., *Chem Biol*, **2014**, 21, 8, 945-54). The activity of MOCCA-POM-C-HMBP was even more striking, with an EC₅₀ value of 0.0039 μ M. This compared favorably to the published value of 0.0054 for the bis-POM analog. Taken together, this data shows minimal differences

between the MOCCA and POM protecting groups of two matched pairs of compounds, suggesting that the MOCCA protecting group has similar prodrug functionality to that of the well-established and clinically-utilized POM protecting group.

5 **Table 2. EC₅₀ values for T cell expansion**

Compound	cmpd	EC ₅₀	Reference
C-HMBP		4000 nM	Hsiao et al.
POM ₂ -C-HMBP	7	5.4 nM	Hsiao et al.
MOCCA-POM-C-HMBP	9	3.9 nM	none
Me-C-HMBP	4	23000 nM	none
POM-Me-C-HMBP		520 nM	Hsiao et al.
MOCCA-Me-C-HMBP	5	18 nM	none

Compounds have potent cell activity – K562 Lysis assays

10 Because the previous experiments utilized 72 hour exposure, the assays may not be sensitive enough to assess subtle differences in the rates of phosphonate release. Therefore, the activity of the novel compounds was assessed in a model of T cell mediated cytotoxicity which occurs with a shorter exposure of just 2 hour (Figure 3).

15 *pH dependence and protein quenching of MOCCA compounds*

The use of the MOCCA prodrugs as probes with which to determine rates of biological deprotection (Figure 4) was examined. All three compounds were readily detected by spectrophotometry with excitation maxima of 360 nm and emission maxima of 410 nm in aqueous solutions. Importantly, the fluorescence intensity of the free MOCCA group was
 20 strongly dependent upon pH of the solvent (Figure 4A), correlating with the expected protonation of the carboxylic acid. At pH 6 the intensity of the free MOCCA group was less than 10% of its intensity at pH 3. At the same time, the fluorescence intensity of the MOCCA prodrugs was not pH dependent. Taken together, the MOCCA prodrugs would be expected to rapidly lose fluorescence intensity during metabolism at neutral pH, as the free MOCCA
 25 group is released from the prodrug and remains in the deprotonated form.

This assay was then adapted to a 384-well-plate format for use in a plate reader equipped with a 355/40 nm excitation filter and a 405/10 nm emission filter. As expected, the fluorescence intensity of MOCCA-Me-C-HMBP in PBS was much higher than that of the free MOCCA group in PBS (Figure 4B). Additionally, the fluorescence of the free MOCCA group was further reduced when incubated in human plasma (Figure 4C). The loss of fluorescence in plasma was likely due to quenching of the MOCCA group, as analysis by thin layer chromatography of plasma extracts confirmed that the MOCCA group had not been destroyed and further spectral analysis did not identify a shift in the excitation or emission spectra. Therefore, the esterase-mediated hydrolysis of MOCCA-Me-C-HMBP could be readily assessed by quantification of the two-step (release followed by quenching) loss of fluorescence following exposure to various biological matrices.

Kinetics of MOCCA-Me-C-HMBP plasma metabolism

The prodrugs and the MOCCA protecting group were stable in PBS (Figure 5A). However, in the presence of plasma MOCCA-Me-C-HMBP decreased with time (Figure 5B), with 2nd order kinetics (Figure 5C) as assessed by spectrophotometry. The half-life was determined to be 7 minutes in this assay. Notably, MOCCA-Me-C-HMBP was metabolized more rapidly relative to the bulkier MOCCA-POM-C-HMBP. In order to confirm that the loss of fluorescence of MOCCA-Me-C-HMBP was indeed due to hydrolysis of the MOCCA-phosphonate ester, the end products were extracted and analyzed by thin layer chromatography. MOCCA-Me-C-HMBP was fully hydrolyzed to yield the free MOCCA group in the presence of human plasma within 40 minutes (Figure 5D). Loss of the prodrug occurred at the same time as the appearance of the MOCCA free acid. The enzymatic release occurred with a half-life of 7.8 minutes in this assay. This indicates that the presence of a bicyclic aromatic group does not prevent enzymatic hydrolysis of the phosphonate ester nor does it permit rapid non-enzymatic degradation.

Kinetics of MOCCA-Me-C-HMBP cellular uptake

The compounds were then used to examine rates of internalization into K562 cells. Surprisingly, K562 cells could rapidly decrease the extracellular concentration of the MOCCA prodrugs. The cellular metabolism of MOCCA-Me-C-HMBP was faster than that of

MOCCA-POM-C-HMBP, though the difference was not as strong as was observed in plasma (Figures 6A and 6B). These findings demonstrate the striking efficacy of phosphonate ester prodrugs. That is, within hours, effectively all of the drug can pass through the cells.

5 Discussion

The utility of using a fluorescent protecting group to enhance cell penetration of a phosphonic acid has been demonstrated. The rate of hydrolysis in plasma is similar to some bis-POM compounds (Farquhar, D., et al., *Journal of Medicinal Chemistry*, **1994**, 37, 23, 3902-3909).

The fluorescence approach of the instant invention is faster and requires smaller volumes of cells relative to radiolabelling approaches (Robbins, B.L., et al., *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 3, 612-617), or HPLC approaches (Eisenberg, E.J., *Nucleosides Nucleotides & Nucleic Acids*, **2001**, 20, 4-7, 1091-1098).

15

All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.


20

CLAIMS


What is claimed is:

1. A conjugate comprising: 1) a therapeutic agent that comprises a phosphate, phosphonate, carboxy, or phosphoramidate group, and 2) a fluorescent group linked to the phosphate, phosphonate, carboxy, or phosphoramidate group to form the corresponding ester.

2. The conjugate of claim 1 wherein the fluorescent group comprises:



3. The conjugate of claim 1 wherein the fluorescent group comprises:



4. The conjugate of claim 1 which comprises one fluorescent group.


5. The conjugate of claim 1 which comprises two fluorescent groups, each linked to a phosphate, phosphonate, carboxy, or phosphoramidate group to form the corresponding ester.

6. The conjugate of any one of claims 1-5 wherein the therapeutic agent comprises a carboxy group.

7. The conjugate of claim 6 wherein the carboxy group of the therapeutic agent is linked to the fluorescent group.


8. The conjugate of any one of claims 1-5 that comprises a phosphonate group of the therapeutic agent linked to the fluorescent group.

9. The conjugate of any one of claims 1-5 wherein the therapeutic agent is:




wherein R^1 is H, (C_1-C_6) alkyl, a prodrug moiety, or a protecting group, or a salt thereof.

10. The conjugate of any one of claims 1-3 wherein the therapeutic agent is:



wherein R^1 is H or a protecting group, or a salt thereof.

11. The conjugate of any one of claims 1-3 wherein the therapeutic agent is:




wherein R^1 is $-OCH_2OC(=O)C(CH_3)_3$, or a salt thereof.

12. The conjugate of any one of claims 1-11 wherein the therapeutic agent is linked to the fluorescent moiety through a linker group that comprises a (C_1-C_6) alkylene.


13. The conjugate of claim 12 wherein the linker group is methylene.

14. The conjugate of claim 1 which is:




wherein R^1 is H, (C_1-C_6) alkyl, a prodrug moiety, or a protecting group, or a salt thereof.

15. The conjugate of claim 1 which is:



wherein R^1 is H or a protecting group, or a salt thereof.

16. The conjugate of claim 1 which is:




wherein R^1 is H or $-OCH_2OC(=O)C(CH_3)_3$, or a salt thereof.

17. The conjugate of claim 16 wherein R^1 is $-OCH_2OC(=O)C(CH_3)_3$, or a salt thereof.

18. The conjugate of claim 1 which comprises a phosphoramidate group.

19. The conjugate of claim 18 which comprises an N-linked amino acid as part of the phosphoramidate group.

20. The conjugate of claim 18 or 19 which comprises the following structure:



wherein:

R^1 is a fluorescent group;


L is absent or is a linking group;

R^2 is an N-linked amino acid;


X is absent or is O; and

R^3 is the residue of a therapeutic agent.


21. The conjugate of claim 20 wherein R^1 -L- is:



22. The conjugate of claim 20 wherein R^1 is:



23. The conjugate of claim 20 wherein R¹ is:



24. The conjugate of any one of claims 20-23 wherein L is a (C₁-C₆)alkylene.
25. The conjugate of any one of claims 20-23 wherein L is methylene.
26. The conjugate of any one of claims 1-8 and 20-23 wherein the therapeutic agent is selected from the group consisting of phosphonates and bisphosphonates.
27. A pharmaceutical composition comprising a conjugate as described in any one of claims 1-26, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
28. A method for treating cancer in an animal comprising administering a conjugate as described in claim 26, or a pharmaceutically acceptable salt thereof, to the animal.
29. A conjugate as described in any one of claims 1-26, or a pharmaceutically acceptable salt thereof, for use in medical therapy.
30. A conjugate as described in claim 26, or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of cancer.
31. The use of a conjugate as described in claim 26, or a pharmaceutically acceptable salt thereof, to prepare a medicament for treating cancer in an animal.

32. A method comprising,
contacting a mammalian cell *in vitro* or *in vivo* with a conjugate as described in any one of claims 1-26 under conditions whereby the conjugate enters the cell; and
measuring the conjugate's fluorescent intensity within the cell or the decrease in fluorescence intensity outside the cell.
33. The method of claim 32, comprising contacting the mammalian cell *in vitro* with the conjugate.
34. The method of claim 32, comprising contacting the mammalian cell *in vivo* with the conjugate.
35. The method of claim 34, wherein the contacting results from administering the conjugate to a mammal.
36. The method of claim 34 or 35, further comprising removing the cell from the mammal after contacting the cell with the conjugate and prior to measuring the conjugate's fluorescent intensity within the cell.
37. A method comprising,
obtaining a biological sample from a mammal comprising one or more cells;
contacting a conjugate as described in any one of claims 1-26 with the biological sample under conditions whereby the conjugate enters the cells; and
measuring the conjugate's fluorescent intensity within the cells or the decrease in fluorescence intensity outside the cells.
38. The method of claim 37, wherein the biological sample comprises cancer cells.
39. The method of claim 37, wherein the biological sample is a blood sample that comprises leukemia cells.

40. The method of any one of claims 32-39, wherein the fluorescent intensity correlates with the amount of conjugate within the cell.
41. The method of any one of claims 32-39, wherein the fluorescent intensity correlates with the amount of therapeutic agent within cells.
42. The method of any one of claims 32-41, further comprising using the fluorescent intensity to determine an appropriate dose of the conjugate or the therapeutic agent to administer to a mammal.
43. The method of any one of claims 32-42, further comprising administering an effective amount of a conjugate of as described in any one of claims 1-26 to the mammal.
44. The method of any one of claims 32-43, wherein the conjugate's fluorescent intensity is measured using spectrophotometry.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/42331

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 12-13, 24-44
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/42331

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - G01N 33/543, G01N 33/53 (2016.01)

CPC - G01N 33/543, G01N 33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): G01N 33/543, G01N 33/53 (2016.01)

CPC: G01N 33/543, G01N 33/53

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
CPC: G01N 33/543, G01N 33/53 (key word limited; see search terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatBase, Google Patents, Google Scholar

Search terms used: conjugate therapeutic agent phosphate phosphonate carboxy or phosphoramidate group fluorescent

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y — A	US 6,172,208 B1 (COOK) 09 January 2001 (09.01.2001); col 1 ln 4-9, 52-53; col 2 ln 15-17; col 4 ln 8-10, 15-16	1-11, 18-23 ----- 14-17
Y — A	US 2005/0208140 A1 (HILFINGER et al.) 22 September 2005 (22.09.2005); para [0010], [0031], [0033], [0052], [0087]	1-11, 18-23 ----- 14-17
Y	US 2003/0162184 A1 (CHOU et al.) 28 August 2003 (28.08.2003); para [0020]-[0021], [0049], [0098]	5, 6/5, 7/5, 8/5, 9/5, 21
Y — A	✓ HSIAO C.-H. C. et al., "Synthesis of a Phosphoantigen Prodrug that Potently Activates V gamma 9V delta 2 T-Lymphocytes", Chemistry & Biology [online], 14 August 2014 (14.08.2014) [retrieved on 2016-09-09], volume 21, issue 8, retrieved from the internet: <DOI: 10.1016/j.chembiol.2014.06.006>, pp. 945-954; see entire document, especially pg 946-947	9-11 ----- 14-17
Y	✓ MAFFRE-LAFON D. et al. "Solid phase synthesis of phosphonopeptides from Fmoc phosphonodipeptides", Tetrahedron Letters [online], 13 June 1994 (13.06.1994) [retrieved on 2016-09-09], volume 35, issue 24, retrieved from the internet: <DOI: 10.1016/S0040-4039(00)73122-4>, pp. 4097-4098; see entire document, especially pg 4098	20-23
A	US 2011/0112054 A1 (JOMAA et al.) 12 May 2011 (12.05.2011); para [0030]	14-17
A	US 2013/0018018 A1 (DONG et al.) 17 January 2013 (17.01.2013); para [0234]	14-17

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

10 September 2016

Date of mailing of the international search report

30 SEP 2016

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774